Pinsky PF, Parnes H. Screening for prostate cancer. N Engl J Med. 2023;388:1405–14.

Article  PubMed  Google Scholar 

Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901–13.

Article  PubMed  Google Scholar 

Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.

Article  PubMed  PubMed Central  Google Scholar 

Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547–58.

Article  PubMed  Google Scholar 

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, et al. Prostate specific antigen density as a predictor of clinically significant prostate cancer when the prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by race and body mass index. J Urol. 2018;200:758–66.

Article  PubMed  Google Scholar 

Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–92.

Article  PubMed  Google Scholar 

Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71:353–65.

Article  PubMed  Google Scholar 

Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.

Article  CAS  PubMed  Google Scholar 

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.

Article  PubMed  Google Scholar 

Li X, Li C, Chen M. Patients With “Gray Zone” PSA levels: application of prostate MRI and MRS in the diagnosis of prostate cancer. J Magn Reson Imaging. 2023;57:992–1010.

Article  PubMed  Google Scholar 

Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol. 2016;195:1428–35.

Article  CAS  PubMed  Google Scholar 

Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60:786–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berger I, Annabattula C, Lewis J, Shetty DV, Kam J, Maclean F. et al. 68)Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis. 2018;21:204–11.

Article  CAS  PubMed  Google Scholar 

Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, et al. Improved specificity with (68)Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nucl Med Mol Imaging. 2019;46:20–30.

Article  PubMed  Google Scholar 

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, et al. Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer. J Urol. 2016;196:1261–7.

Article  CAS  PubMed  Google Scholar 

Donato P, Roberts M, Morton A, Kyle S, Coughlin G, Esler R, et al. Improved specificity with Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nuclear Med Mol Imaging. 2019;46:20–30.

Article  Google Scholar 

Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023;84:36–48.

Article  PubMed  Google Scholar 

Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, et al. Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int. 2019;124:42–49.

Article  CAS  PubMed  Google Scholar 

Mookerji N, Pfanner T, Hui A, Huang G, Albers P, Mittal R, et al. Fluorine-18 prostate-specific membrane antigen-1007 PET/CT vs multiparametric MRI for locoregional staging of prostate cancer. JAMA Oncol. 2024;10:1097–103.

Article  PubMed  PubMed Central  Google Scholar 

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system Version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76:340–51.

Article  PubMed  Google Scholar 

Luo L, Zheng A, Chang R, Li Y, Gao J, Wang Z, et al. Evaluating the value of (18)F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard. Cancer Imaging. 2023;23:108.

Article  PubMed  PubMed Central  Google Scholar 

Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the Diagnosis of Prostate Cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682–9.

Article  CAS  PubMed  Google Scholar 

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767–77.

Article  PubMed  PubMed Central  Google Scholar 

Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N et al. Fluorine-18-labelled prostate-specific membrane antigen positron emission tomography/computed tomography or magnetic resonance imaging to diagnose and localise prostate cancer. A Prospective Single-arm Paired Comparison (PEDAL). Eur Urol Oncol 2024. https://doi.org/10.1016/j.euo.2024.01.002.

Walz J. Better to rule in or rule out significant prostate cancer? The added value of prostate-specific membrane antigen positron emission tomography to magnetic resonance imaging diagnostic pathways for prostate cancer. Eur Urol Oncol. 2022;5:401–2.

Article  PubMed  Google Scholar 

Yang J, Tang Y, Zhou C, Zhou M, Li J, Hu S. The use of (68) Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk. Prostate. 2023;83:430–9.

Article  CAS  PubMed  Google Scholar 

Prive BM, Israel B, Janssen MJR, van der Leest MMG, de Rooij M, van Ipenburg JA, et al. Multiparametric MRI and (18)F-PSMA-1007 PET/CT for the detection of clinically significant prostate cancer. Radiology. 2024;311:e231879.

Article  PubMed  Google Scholar 

Chen M, Zhang Q, Zhang C, Zhao X, Marra G, Gao J, et al. Combination of (68)Ga-PSMA PET/CT and Multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis. J Nucl Med. 2019;60:944–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wondergem M, van der Zant FM, Broos WAM, Knol RJJ. Matched-Pair Comparison of (18)F-DCFPyL PET/CT and (18)F-PSMA-1007 PET/CT in 240 prostate cancer patients: interreader agreement and lesion detection rate of suspected lesions. J Nucl Med. 2021;62:1422–9.

Article  CAS  PubMed  Google Scholar